Posts Tagged ‘Heparin’

Part B MAC Says it Will Deny Heparin, J1642

Friday, June 11th, 2010

Medicare does not allow for separate payment of Heparin when used to facilitate a flush during or following a drug infusion; nor should a separate administration code be billed for providing the heparin. To reduce the number of inappropriate paid claims received for this service, TrailBlazer Health Enterprises posted a June 10 notice on its website stating it will begin denying HCPCS Level II code J1642 Injection, heparin sodium, (heparin lock flush), per 10 units effective July 14.

According to Medicare Internet-Only Manual (IOM) Pub. 100-04, Chapter 12, Section 30.5, Medicare does not separately pay the services listed below considered part of the drug administration:

“A therapeutic, prophylactic, or diagnostic IV [intravenous] infusion or injection, other than hydration, is for the administration of substances/drugs. The fluid used to administer the drug(s) is incidental hydration and is not separately payable. If performed to facilitate the infusion or injection or hydration, the following services and items are included and are not separately billable:

  • Use of local anesthesia
  • IV start
  • Access to indwelling IV, subcutaneous catheter or port
  • Flush at conclusion of infusion
  • Standard tubing, syringes and supplies

Payment for the above is included in the payment for the chemotherapy administration or non-chemotherapy injection and infusion service.”

TrailBlazer is Part A and Part B Medicare Administrative Contractor (A/B MAC) for Jurisdiction 4, which includes Colorado, New Mexico, Oklahoma, Texas, and Indian Health Service.

Propofol Demand Remains High Despite Controversy

Friday, June 11th, 2010

Where there were two U.S. drug manufacturers of the popular sedative drug propofol, now there are none. Teva Pharmaceuticals Industries announced May 28 that it would continue to market its current supply but would make no more of the anesthetic. Hospira Inc. suspended production of the drug last month. Both companies have dealt with a multitude of propofol-related manufacturing problems.

Read more »

Health Alert: New Heparin Less Potent

Monday, October 5th, 2009

The Food and Drug Administration (FDA) advised health care professionals Oct. 1 that a new version of heparin due to start shipping Oct. 8 is 10 percent less potent, and that this reduced potency could weaken its ability to prevent blood clots. Read more »

FDA Seizes Contaminated Heparin

Tuesday, November 18th, 2008

The U.S. Food and Drug Administration (FDA) seized 11 lots of contaminated heparin—a blood thinner drug—from Celsus Laboratories Inc. on Nov. 6, according to an FDA news release.

The 11 lots consisted of five lots of Heparin Sodium Active Pharmaceutical Ingredient (API) and six lots of Heparin Lithium. These products were manufactured in China and found to be contaminated with over-sulfated chondroitin sulfate (OSCS)—a substance that mimics heparin’s anticoagulant activity. Read more »